Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: SHR0302 OintmentDrug: Vehicle
- Registration Number
- NCT04717310
- Lead Sponsor
- Reistone Biopharma Company Limited
- Brief Summary
This is a Randomized, Double-blind, Vehicle-Controlled, Seamless and Adaptive-designed Phase II/III Study to Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Adult Patients with Mild-to-Moderate Atopic Dermatitis.
It will consist of phase II and phase III parts, phase II will be a dose-ranging part and phase III will be a pivotal study part.
- Detailed Description
This study will evaluate the topical SHR0302 ointment, a JAK (Janus Kinase) inhibitor, in atopic dermatitis patients. The EASI (Eczema Area and Severity Index), IGA (immunoglobulin A), SCORAD (Scoring of Atopic Dermatitis),DLQI (Dermatology Life Quality Index)and NRS (Numeric Rating Score) will be applied to assesses to the efficacy, and other safety measurements will be also collected within the whole study duration.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 645
-
Male or female subject at least at ≥18 and ≤75years of age at time of informed consent.
-
Have mild-to- moderate AD (Atopic Dermatitis), as determined by all of the following:
- Were diagnosed with AD (defined by the Hanifin and Rajka criteria)
- With AD history at least 6 months
-
Capable of providing a signed and dated informed consent form indicating the subject has been informed of all pertinent aspect of the study
-
All women of childbearing potential and all men must be willing to use at least one highly effective method of contraception from signing of informed consent, throughout the duration of the study, and for 28 days after last dose of study medication.
- Subjects currently have active forms of other skin disease (e.g., psoriasis, or lupus erythematosus) that would interfere with evaluation of the effect of study medication on atopic dermatitis, or skin infections (bacteria, fungi, or viruses), or diseases that can cause skin itching (such as itching caused by diabetes), or subjects who are allergic to topical skin drugs
- Subjects with serious concomitant illness that could require administering of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g. unstable chronic asthma)
- Subjects who have a history of mental illness or disease such as anxiety and depression, and are not suitable to participate in this study
- Subjects with serious and uncontrolled disease that may affect the safety of the subject, compliance, affect the evaluation of the endpoint, or require the use of drugs that are not allowed in the protocol
- Subjects with Human immunodeficiency virus (HIV), or hepatitis B virus ,or hepatitis C virus ,or syphilis related laboratory test positive (subjects positive for hepatitis B surface antigen, HBV (hepatitis B virus) DNA must be greater than lower limit of detection
- Subjects with malignant tumors or a history of malignant tumors, except for fully treated or resected skin non-metastatic basal cell carcinoma or squamous cell carcinoma
- Pregnant female subjects, breastfeeding female subjects, or male subjects able to father children and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in protocol for the duration of the study and for at least 28 days after last dose of investigational product.
- The investigators determined that there were conditions that affected the safety and efficacy of the investigational drug
- Subjects who, in the opinion of the investigator or Reistone, will be unsuitable for inclusion in the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Active Comparator: SHR0302 Ointment Dose#1 SHR0302 Ointment Drug: SHR0302 Ointment Twice a day (BID) Active Comparator: SHR0302 Ointment Dose#3 SHR0302 Ointment Drug: SHR0302 Ointment Twice a day (BID) Active Comparator: SHR0302 Ointment Dose#2 SHR0302 Ointment Drug: SHR0302 Ointment Twice a day (BID) Placebo Comparator: Placebo Vehicle Drug: Vehicle Twice a day (BID)
- Primary Outcome Measures
Name Time Method Percentage change from baseline in the eczema area and severity index (EASI) total score at Week 8 8 weeks The percentage of subjects achieving the Investigator's Global Assessment（IGA）of clear (0) or almost clear (1) with a ≥2 points improvement from baseline at Week 8
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (31)
Hangzhou First People's Hospital
🇨🇳Hangzhou, Zhejiang, China
Hangzhou Third People's Hospital
🇨🇳Hangzhou, Zhejiang, China
Zhejiang province People's Hospital
🇨🇳Hangzhou, China
Beijing Hospital
🇨🇳Beijing, Beijing, China
Anhui Provincial Hospital
🇨🇳Hefei, Anhui, China
Beijing Friendship Hospital, Capital Medical University
🇨🇳Beijing, Beijing, China
Chongqing Traditional Chinese Medicine Hospital
🇨🇳Chongqing, Chongqing, China
Xinqiao Hospital of AMU
🇨🇳Chongqing, Chongqing, China
The First Hospital Affiliated to AMU (Southwest Hospital)
🇨🇳Chongqing, Chongqing, China
The First Affiliated Hospital of Fujian Medical University
🇨🇳Fuzhou, Fujian, China
The First Affiliated Hospital Sun Yat-sen University
🇨🇳Guangzhou, Guangdong, China
Dermatology Hospital of Southern Medical University
🇨🇳Guangzhou, Guangdong, China
Nanyang first people's Hospital
🇨🇳Nanyang, Henan, China
Wuhan NO.1 Hospital
🇨🇳Wuhan, Hubei, China
Affiliated Hospital of Guizhou Medical University
🇨🇳Guiyang, Guizhou, China
The Second Xiangya Hospital of Central South University
🇨🇳Changsha, Hunan, China
The Second People's Hospital of Wuxi
🇨🇳Wuxi, Jiangsu, China
Jiangxi Provincial Hospital of Dermatology
🇨🇳Nanchang, Jiangxi, China
The Second Hospital of Jilin University
🇨🇳Chang chun, Jilin, China
Affiliated Hospital of Jiangsu University
🇨🇳Zhenjiang, Jiangsu, China
Shengjing Hospital of China Medical University
🇨🇳Shenyang, Liaoning, China
Shanghai Skin Disease Hospital
🇨🇳Shanghai, Shanghai, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
🇨🇳Shanghai, Shanghai, China
West China Hospital of Sichuan University
🇨🇳Chengdu, Sichuan, China
Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
🇨🇳Tianjin, Tianjin, China
SIR RUN RUN Shaw Hospital Zhejiang University School of Medicine
🇨🇳Hangzhou, Zhejiang, China
The First Affiliated Hospital of Wenzhou Medical University
🇨🇳Wenzhou, Zhejiang, China
Hwa Mei Hospital
🇨🇳Ningbo, Zhejiang, China
The Third Xiangya Hospital of Central South University
🇨🇳Changsha, China
Huashan Hospital Fudan University
🇨🇳Shanghai, China
Sun. Yat- Sen Memorial Hospital, Sun. Yat- Sen University
🇨🇳Guangzhou, China